2.A Study on the Serum Lipid Level In Hypertensive Patients.
Shee Juhn CHUNG ; Kyung Soo KIM
Korean Circulation Journal 1991;21(1):125-128
The plasma cholesterol, TG,LDG,HDL of 101 Korean hypertensive patients were measured to compare with plasma cholesterol, TG,LDL,HDL level of healthy people(control group). The plasma cholesterol level in hypertensive patients was 189.6+/-39.5mg% and was 188.7+/-33.7mg% in healthy people(P>0.5). The plasma TG level in hypertensive patients was 200.5+/-154.2mg% and was 116.1+/-32.4mg% in healthy people(P<0.05). The plasma HDL level in hypertensive patients was 44.6+/-15.5mg% and was 45.1+/-9.8mg% in healthy people(P>0.05). The plasma LDL level in hypertensive patients was 119.0+/-68.6mg% and was 98.1+/-53.4mg% in healthy people(P>0.05). The serum level of the total cholesterol, HDL and LDL cholesterol in the hypertensive patients group were not significantly different from the control group, but the serum level of the TG was significantly increased in the patients group. We thought that this difference of plasma TG level is due to exogenous TG in hypertensive patient group but further evalution in properties of TG is required.
Cholesterol
;
Cholesterol, HDL
;
Cholesterol, LDL
;
Humans
;
Plasma
3.Serum lipid profile in children with different subtypes of juvenile idiopathic arthritis.
Dong-Ming SUN ; Yan DING ; Yong ZHNAG ; Kun XIA
Chinese Journal of Contemporary Pediatrics 2019;21(6):547-551
OBJECTIVE:
To study the serum lipid profile in children with different subtypes of juvenile idiopathic arthritis (JIA) during active and remission stages, as well as the long-term risk of atherosclerosis in children with JIA.
METHODS:
A total of 128 children newly diagnosed with active JIA were divided into oligoarticular JIA group with 48 children, polyarticular JIA group with 38 children, systemic JIA group with 22 children, and enthesitis-related JIA group with 20 children. According to the presence or absence of rheumatoid factor (RF), the polyarticular JIA group was further divided into RF-positive polyarticular JIA group with 15 children and RF-negative polyarticular JIA group with 23 children. A total of 45 children who underwent physical examination were randomly selected as healthy control group. The serum levels of total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were measured and compared between groups. Blood lipid parameters were reexamined for 87 children in the remission stage after treatment and were compared with those in the active stage.
RESULTS:
Compared with the healthy control group, the systemic JIA group and the RF-positive polyarticular JIA group had a significant reduction in HDL-C and a significant increase in TG (P<0.05) in the active stage, while there were no significant differences in TC and LDL-C (P>0.05). There were no significant differences in blood lipid parameters between the other subtype JIA groups and the healthy control group (P>0.05). The RF-positive polyarticular JIA group had a significant increase in plasma HDL-C from the active stage to the remission stage (P<0.05), while the other subtype JIA groups had no significant changes in blood lipid parameters (P>0.05).
CONCLUSIONS
Dyslipidemia may be observed in the active stage of children with systemic and RF-positive polyarticular JIA, with improvement in the remission stage of children with RF-positive polyarticular JIA. Further studies are needed to observe the long-term risk of atherosclerosis.
Arthritis, Juvenile
;
Child
;
Cholesterol, HDL
;
Humans
;
Triglycerides
4.Effect of Lovastatin on Serum Lipids in Primary Hypercholesterolemia.
Wee Hyun PARK ; Shin Woo KIM ; Eon Jo WOO ; Seung Wan KANG ; Jin Yong HWANG ; Shung Chull CHAE ; Jae Eun JUN
Korean Circulation Journal 1991;21(2):322-327
10 Patients with primary hypercholesterolemia were treated for 12 weeks with lovastation(20mg t.i.d). Lovastatin reduced mean total and low density lipoprotein cholesterol by 43% and 57% respectively(p<0.001). High density lipoprotein cholesterol and triglyceride levels were unchanged by the drug. Adverse effects attributable to lovastatin were not observed. Thus lovastatin is considered as an effective lipid lowering agent for the treatment of primary moderate hypercholesterolemia.
Cholesterol, HDL
;
Cholesterol, LDL
;
Humans
;
Hypercholesterolemia*
;
Lovastatin*
;
Triglycerides
6.Antioxidative Activity after Rosuvastatin Treatment in Patients with Stable Ischemic Heart Disease and Decreased High Density Lipoprotein Cholesterol.
Do Sim PARK ; Kyeong Ho YUN ; Hyun Young PARK ; Sang Jae RHEE ; Nam Ho KIM ; Seok Kyu OH ; Jin Won JEONG
Korean Circulation Journal 2016;46(3):309-314
BACKGROUND AND OBJECTIVES: The clinical significance of statin-induced high-density lipoprotein cholesterol (HDL-C) changes is not well known. We investigated whether rosuvastatin-induced HDL-C changes can influence the anti-oxidative action of high-density lipoprotein particle. SUBJECTS AND METHODS: A total of 240 patients with stable ischemic heart disease were studied. Anti-oxidative property was assessed by paraoxonase 1 (PON1) activity. We compared the lipid profile and PON1 activity at baseline and at 8 weeks after rosuvastatin 10 mg treatment. RESULTS: Rosuvastatin treatment increased the mean HDL-C concentration by 1.9±9.2 mg/dL (6.4±21.4%). HDL-C increased in 138 patients (57.5%), but decreased in 102 patients (42.5%) after statin treatment. PON1 activity increased to 19.1% in all patients. In both, the patients with increased HDL-C and with decreased HDL-C, PON1 activity significantly increased after rosuvastatin treatment (+19.3% in increased HDL-C responder; p=0.018, +18.8% in decreased HDL-C responder; p=0.045 by paired t-test). Baseline PON1 activity modestly correlated with HDL-C levels (r=0.248, p=0.009); however, the PON1 activity evaluated during the course of the treatment did not correlate with HDL-C levels (r=0.153, p=0.075). CONCLUSION: Rosuvastatin treatment improved the anti-oxidative properties as assessed by PON1 activity, regardless of on-treatment HDL-C levels, in patients with stable ischemic heart disease.
Aryldialkylphosphatase
;
Cholesterol
;
Cholesterol, HDL*
;
Humans
;
Hydroxymethylglutaryl-CoA Reductase Inhibitors
;
Lipoproteins
;
Lipoproteins, HDL
;
Myocardial Ischemia*
;
Rosuvastatin Calcium*
8.Hypolipidemic Effects and Safety of Lovastatin in Patients with Primary Hypercholesterolemia.
Jong Hoa BAE ; Chung Whee CHOUE ; Kwon Sam KIM ; Myung Shick KIM ; Jung Sang SONG
Korean Circulation Journal 1991;21(1):129-136
To evaluate the efficacy and safety of lovastatin, new hypolipidemic agent of HMG-CoA reductase inhibitor, we administered lovastatin 40mg to 80mg once daily for 12 weeks in 20 patients(7 males, 13 females) with primary hypercholesterolemia, and observed the sequential chamges of the lipid profile every 4 weeks. The results are as follows ; 1) The seurm total cholesterol was reduced significantly by 31% from 321+/-36mg% to 210+/-26mg%(p<0.05). 2) The serum triglycerides was significantly reduced from 321+/-168mg% to 228+/-74mg% by 29%(p<0.05). 3) The low density lipoprotein cholesterol was reduced significantly from 177+/-36mg% to 120+/-22mg% by 32%(p<0.05). 4) The total lipid, high density lipoprotein cholesterol and very low density lipoprotein cholesterol were also reduced significantly. 5) The ratio between total cholesterol and high density lipoprotein cholesterol, low density lipoprotein cholesterol and high density lipoprotein cholesterol did not change after lovastatin therapy. 6) There was no adverse reaction due to lovastatin therapy during 12 weeks of therapy. These results suggested that lovastatin is a effective and safe now hypolipidemic agent and is a convenient HMG-CoA reductase inhibitor for clinical use.
Cholesterol
;
Cholesterol, HDL
;
Cholesterol, LDL
;
Cholesterol, VLDL
;
Humans
;
Hypercholesterolemia*
;
Lovastatin*
;
Male
;
Oxidoreductases
;
Triglycerides
9.The Relationship between Job Stress and Dyslipidemia in Express Bus Drivers.
Nam Soo LEE ; Kyung Jae LEE ; Joo Ja KIM ; Jin Woo LEE
Korean Journal of Occupational and Environmental Medicine 2010;22(3):221-229
OBJECTIVES: To examine whether or not there is a relationship between job stress and dyslipidemia in male express bus drivers. METHODS: The study subjects were 301 male express bus drivers. The data was obtained from annual health surveillance. A structured questionnaire was used to assess sociodemographics, health-related behaviors and job characteristics. Job stress was measured by the Korean Occupational Stress Scale-Short Form. A measure of blood lipid levels, comprised of total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides, was dichotomized and categorized into 'high' or 'low'. Multiple logistic regression modeling was used to determine an association between job stress and dyslipidemia, with blood lipid level as the dependent variable. RESULTS: We found that high job demand was associated with high total cholesterol (OR 3.25, 95% CI 1.18-8.95) and high LDL-cholesterol (OR 4.14, 95% CI 1.18-14.44) and lack of job control was associated with low HDL-cholesterol (OR 1.92, 95% CI 1.04-3.56). CONCLUSION: These results indicate that job demand and lack of job control were associated with dyslipidemia in male express bus drivers. A job stress management program that emphasizes job demand and lack of job control is needed to prevent dyslipidemia in male express bus drivers.
Cholesterol
;
Cholesterol, HDL
;
Cholesterol, LDL
;
Dyslipidemias
;
Humans
;
Logistic Models
;
Male
;
Questionnaires
;
Triglycerides
10.Seasonal Variations of Serum Lipid Concentrations in Health Screened Population.
Bum Soo KIM ; Jin Ho KANG ; Kyung Soo KIM ; Sang Jong LEE ; Man Ho LEE ; Jung Ro PARK
Korean Circulation Journal 1998;28(7):1122-1130
BACKGROUND AND OBJECTIVES: Significant seasonal variations have been found by several authors in serum lipids. The aim of this study was to determine whethere there were seasonal variations in serum lipid concentrations in Korean healthy population. METHODS AND MATERIALS: The subjects consisted of 20,819 men and 10,248 women screened between January in 1997 and December in 1997. We performed spectral analyses to confirm whether there is seasonal variation in serum lipid levels. RESULTS: The monthly serum total cholesterol, HDL cholesterol and LDL cholesterol levels were significantly higher in the period from September to December with the peak in October (p<0.001, except, HDL cholesterol p<0.02), and by the seasonal analysis, these lipid levels in autumn were significantly higher than those in spring and summer (p<0.001). Those patterns of monthly and seasonal variations were similar in both men and women. Howevere triglycerides levels were slightly different by the sex. In men, significantly increased triglycerides levels were found in the period from August to December with the peak in September and those in autumn were the highest (p<0.025). In women, serum triglycerides levels were significantly higher in the period from July to February with the peak in December (p<0.04). Serum triglyceride levels in winter were higher compared with in spring and summer (p<0.001). Additionally, we analysed the seasonal variations of serum lipid levels according to the body mass index (BMI) and the age groups. In these analysis, there were also similar patterns of seasonal variations in serum lipid levels (p<0.001). CONCLUSIONS: Above results show that there were prominent seasonal variations of serum lipid levels with higher in autumn and winter compared with those in spring and summer.
Body Mass Index
;
Cholesterol
;
Cholesterol, HDL
;
Cholesterol, LDL
;
Female
;
Humans
;
Male
;
Seasons*
;
Triglycerides